Andrew Maxwell

Andrew Maxwell has a wealth of Medical Technology experience. For 10 years, Mr Maxwell led the global growth of Global Kinetics Corporation (GKC) as managing director and chief executive. GKC commercialised a research project emanating from the Florey Institute of Neuroscience and Mental Health, and created a global company with a market-leading product for the remote measurement, and reporting of the movement disorder symptoms of Parkinson’s disease. GKC gained FDA clearance in the USA, Class 1 and Class 2a CE mark in Europe and TGA registration in Australia for its Parkinson’s KinetiGraph (PKG) and PKG Watch, a wearable medical device and a mobile health IT software system. GKC was the sponsor manufacture of product and via its own direct sales and marketing team, implemented the PKG in over 140 hospitals in 16 countries providing more than 65,000 people with Parkinson’s access to a clinical test that will make a meaningful difference to the management of their condition. Prior to GKC, as chief executive of ESCOR Private Equity (a Smorgon Family Company), Mr Maxwell established and managed a $40m investment fund focused on investing in the IT, Internet, Biotech, and Healthcare sectors in Australia, the USA and Europe. Mr Maxwell was also a member of the ESCOR Group Investment Coordination Committee, evaluating capital allocation and investments strategy for the ESCOR Group.
Bio last updated 19 Jul 2017

Article Timeline

Access to our data for Andrew Maxwell is only available to paid subscribers with access.

The search engine is Western Australia's most accurate and comprehensive business listings and searchable database.

Andrew Maxwell is linked to 1 organisation which is included in 1 list - Public Companies - Industrial.

To see the data you will need to .

Total Shareholder Return as at 30/11/18

1 year TSR5 year TSR
24thProteomics International Laboratories167%
248thMejority Capital5%-8%
446thTransaction Solutions International-22%-0%
741 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Source: Morningstar


Non-Executive Director
Year started and most recent title


128th↑Transaction Solutions International$2.3m
129th↓Proteomics International Laboratories$2.1m
132nd↓Mejority Capital$2.1m
239 listed industrial companies ranked by revenue.
Source: Morningstar

BNiQ Disclaimer